Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group.
Christine L PhillipsAdam LaneRobert B GerbingTodd A AlonzoAlyss WilkeyGretchen RadloffBeverly LangeEric R GamazonM Eileen DolanStella M DaviesPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
We report clinical importance of two SNPs not previously associated with cytarabine toxicity. Moreover, we confirm that SNP rs17202778 significantly impacts TRM in pediatric AML. Cytarabine sensitivity genotypes may predict TRM and could be used to stratify to standard versus high-dose cytarabine regimens, warranting further study in prospective AML trials.
Keyphrases
- acute myeloid leukemia
- high dose
- allogeneic hematopoietic stem cell transplantation
- genome wide
- low dose
- copy number
- stem cell transplantation
- young adults
- palliative care
- cardiovascular events
- gene expression
- type diabetes
- cardiovascular disease
- dna methylation
- combination therapy
- acute lymphoblastic leukemia
- oxide nanoparticles